ORLANDO – Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data demonstrating the feasibility of long-term, low-dose adjuvant chemotherapy, which resulted in fewer tumor recurrences and cancer metastases in patients with locally advanced head and neck squamous cell carcinoma. The findings were announced today at the 2009 American Society of Clinical Oncology Annual Meeting. Read the rest of this entry »

DETROIT – Cancer survivors, their families and caregivers are invited to attend the 5th Annual Survivorship University Celebration of Survivorship event, June 18, presented by the Barbara Ann Karmanos Cancer Institute. The celebration recognizes cancer survivors who raise awareness of cancer prevention and help empower lives. The Patricia Milner Sachs Heart of a Survivor Award will be given to an outstanding cancer survivor who exemplifies caring compassion and devotion; someone who goes above and beyond to help other cancer survivors on their journey Read the rest of this entry »

BUFFALO, NY – Roswell Park Cancer Institute (RPCI) was honored with the Oncology Nursing Certification Corporation (ONCC) 2009 Employer Recognition Award. ONCC recognizes one organization each year for its sustained support of oncology nursing certification.

Read the rest of this entry »

Source:
1. New Treatment Strategy Enhances Outcome for Lung Cancer

SHOW THE TRUTH. PICTURE WARNINGS SAVE LIVES

Read the rest of this entry »

BUFFALO, NY- A new cancer drug shows promising results in patients with metastatic cancer. The phase I clinical trial research will be presented by Alex A. Adjei, MD, PhD, Senior Vice President for Clinical Research and the Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park Cancer Institute (RPCI), at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 – June 2, in Orlando, FL.

Read the rest of this entry »

BUFFALO, NY- Patients diagnosed with non-Hodgkin’s lymphoma who become resistant to standard therapies may have a new treatment option. Scientists in the Lymphoma Translational Research Laboratory at Roswell Park Cancer Institute analyzed the mechanisms to overcome treatment resistance, including a new drug combination. Francisco J. Hernandez-Ilizaliturri, MD, Departments of Medicine and Immunology, Roswell Park Cancer Institute (RPCI), will present the findings at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 – June 2, in Orlando, FL.

Read the rest of this entry »

BUFFALO, NY- Roswell Park scientists are investigating a new combination of drugs for colorectal cancer patients who have become intolerant or resistant to standard therapies. Marwan Fakih, MD, Department of Medicine at Roswell Park Cancer Institute will present the results of a phase I clinical study at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 – June 2, in Orlando, FL.

Read the rest of this entry »

PITTSBURGH, May 30, 2009 – Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, MD, associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI). The results will be disclosed at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) on May 30 in Orlando, Fla.

Read the rest of this entry »

PITTSBURGH, May 30, 2009 – Researchers from the University of Pittsburgh Cancer Institute (UPCI) have identified eight genes that help predict a melanoma patient's response to treatment. The new findings are being presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO), May 29 to June 2, in Orlando, Fla.

Read the rest of this entry »